A Study on Thyroid Dysfunction in HIV Infected Individuals by Aparna, S
A STUDY ON THYROID DYSFUNCTION IN HIV
INFECTED INDIVIDUALS
Dissertation submitted in partial fulfillment of
Requirements for
M.D.DEGREE IN GENERAL MEDICINE
BRANCH - I
of
THE TAMILNADU Dr.M.G.R. MEDICAL UNIVERSITY
CHENNAI
GOVERNMENT KILPAUK MEDICAL COLLEGE
CHENNAI - 10
APRIL 2011
BONAFIDE CERTIFICATE
This is to certify that "A STUDY ON THYROID DYSFUNCTION IN HIV
INFECTED INDIVIDUALS" is a bonafide work done by Dr.Aparna.S, post
graduate student, Department of General Medicine, Kilpauk Medical
College, Chennai-10, under my guidance and supervision in partial
fulfillment of regulations of The Tamilnadu  Dr.M.G.R. Medical University
for  the  award  of M.D. Degree Branch I (General Medicine) during the
academic period from May 2008 to April 2011.
Dr. V.Kanagasabai, M.D.,
Dean Kilpauk Medical
College, Chennai- 10
Prof.G.Rajendran, M.D., Prof. N.Raghu M.D.,
Professor and Head, Professor,
Department of Internal Medicine, Department of Internal Medicine,
Kilpauk Medical College, Kilpauk Medical College,
Chennai-10. Chennai -10.
ACKNOWLEDGEMENT
At  the  outset  I  thank  Prof.  V. Kanagasabai,  M.D.,  Dean,   Kilpauk
Medical   College,   for   having   permitted   me   to   use   the   hospital
resources  for the study.
I am extremely grateful to Prof. Dr. G. Rajendran, Professor and Head of
the Department of Internal Medicine, Kilpauk Medical College, Chennai
for permitting me to carryout this study and for his constant
encouragement and guidance.
I owe my sincere gratitude to my chief  Prof.  N.  Raghu, MD.,
Department of Internal Medicine, Kilpauk Medical College, Chennai for
his inspiration, advice, comments, corrections and guidance in making
this work complete.
I also express my sincere gratitude to Prof. A. Joseph Navaseelan, MD.,
Prof. D. Varadharajan, MD., and Prof. B. Chellam, MD.,
Prof. M.D. Selvam, MD., for their help and guidance rendered during the
entire period of my work.
I   express   my   deep   gratitude   to Dr. R. Kulothungan, MD.,
Dr. S. Parimalasundari, MD., and Dr. M. Malarvizhi, MD., Assistant
Professor,  Department of  Internal  Medicine,  Kilpauk Medical College,
Chennai for  their  inspiration,  advice, comments, corrections and
guidance in making this work complete.
I whole heartedly express my sincere thanks to Dr. K. Nandagopal, DV.,
Medical Officer, ART centre, Kilpauk Medical College, Chennai for his
valuable guidance and support throughout my dissertation work.
I also extend my thanks to all the laboratory technicians, staff and
statistician in Kilpauk Medical College, Chennai for their valuable
support throughout my dissertation work.
I also thank my family members, colleagues and friends for their moral
support and encouragement throughout my dissertation work.
Last but not the least, with sincere gratitude I thank all the patients who
contributed so much to this study without whom this study could not have
been possible.
CONTENTS
S.NO. TITLE
PAGE
NO.
1. INTRODUCION 1
2. AIM 4
3. REVIEW OF LITERATURE 5
4. MATERIALS AND METHODS 35
5. RESULTS AND ANALYSIS 40
6. DISCUSSION 52
7. CONCLUSION 60
8. ANNEXURES
Proforma
Master Chart
Charts
9. BIBLIOGRAPHY
INTRODUCTION
INTRODUCTION
Acquired Immuno Deficiency Syndrome was first recognized in
the United States in 1981 when the U.S Centre for Disease Control and
prevention (CDC) reported unexplained occurrence of Pneumocystis
jiroveci pneumonia in five previously healthy homosexual men. Within
months, disease was recognized in injection drugs users (IDUs), in
recipient of  blood transfusions and hemophiliacs.
In 1983, Human Immuno Deficiency Virus was isolated from a
patient with lymphadenopathy and in 1984 it was demonstrated clearly to
be the causative agent of AIDS.1 India’s first case of AIDS was reported
in 1986 from Chennai.2
Human immunodeficiency virus (HIV) infection can lead to
multiple organ involvement including the endocrine system. Endocrine
function may be altered in these subjects because of the possible
relationship between the immune and endocrine systems, direct
involvement of the glands by the HIV itself, opportunistic infections or
malignancies.3&4
Abnormal thyroid functions in these patients may be caused by the
stress of advanced disease or concomitant morbidities and may manifest
as the classic sick euthyroid syndrome probably due to a hypothalamic
pituitary deficit related to the progress of immunodeficiency and
cachexia.3 Cytokines such as IL-6 and TNF-? can acutely decrease TSH
and T3 and increase rT3 levels. LoPresti et al studied thyroid functions in
HIV positive patients, to evaluate if they could be used to predict their
progression and outcome.
Jain et al reported abnormal thyroid levels which correlated with
the CD4 counts and severity of the disease.5
Screening studies have demonstrated an increased prevalence of
primary hypothyroidism in HIV infected patients. Beltran4 reported overt
hypothyroidism in 2.6%, subclinical hypothyroidism in 6.6% and an
isolated low T4 level in 6.8% of 350 subjects studied. Low free T4 levels
(1.3%) and subclincal hypothyroidism (3.5%) which correlated with low
CD4 counts were reported in a Spanish population.6
An infectious trigger for immune activation (by molecular
mimicry) is one of the postulated mechanisms for autoimmune disease.
However hypothyroidism in HIV infected patients is not associated with
autoimmunity.10 one case of Hashimoto’s hypothyroidism has been
reported so far after highly active anti-retroviral therapy (HAART)
initiation.7
Subclinical hypothyroidism is more prevalent in the HIV infected
population, compared to HIV-negative individuals.8&9 Quirino8 reported a
similar prevalence of subclincal hypothyroidism in both naive and
HAART treated subjects,
Beltran et al12 found that subclinical hypothyroidism was
associated  with  the  use  of  stavudine  and  lower  CD4+  cell  count,  The
cumulative daily dose of both stavudine and lamivudine was significantly
related to the presence of hypothyroidism in Grappin’s series.9
Didanosine and ritonavir were associated with a low free T4.
Madge et al 10 found the prevalence of hypothyroidism to be 2.5%
(overt) and 4% (subclinical). Hyperthyroidism (overt and subclinica) l
occurred in <1%.of patients.
Nelson’s study11 revealed a higher than expected incidence of overt
hyopothyroidism in patients receiving HAART and they recommend
universal screening of subjects on therapy.
Inview of abnormal TFT encountered often in HIV positive
individuals and HIV patients on HAART, it was decided to undertake a
study of thyroid function on HIV infected patients at Kilpauk Medical
College Hospital, Chennai.
  AIM
AIMS OF THE STUDY
? To study the prevalence of thyroid dysfunction in HIV infected
patients.
? To compare thyroid dysfunction in pre ART HIV individuals with
individuals on HAART.
? To study thyroid function test in patients with HIV at various
stages of illness and co-relate their results with disease progression.
  REVIEW OF LITERATURE
REVIEW OF LITERATURE
HIV evolved from simian immunodeficiency virus (SIV) in
chimpanzees and monkeys.  Surprisingly,  in  its  natural  host,  SIV  does
not cause  disease,  despite  replicating  to  high  levels  in  infected
animals.  This lack of pathogenicity may be from a lack of T cell
activation in these hosts.
Alternatively,  these  species  may  have  developed  tolerance  to
the  infection through natural selection.13&14  Data suggest that humans
acquired HIV type 1 (HIV-1) from Pan troglodytes troglodytes
chimpanzees infected with SIV, and  that   HIV-1  was  introduced  into
the  human  population  (as  SIV) from these  chimpanzees  on  at  least
three  independent 15 HIV-2 originated from the sooty mangabey monkey
(Cercocebus atys).16
Since   its   identification   in   early   eighties,   HIV   has   attained
epidemic proportions  inspite  of  it  being  designated  as  biosafety  level
2  pathogen.17 The distribution of the spread is such that its incidence is
racing alarmingly in Sub-Saharan Africa, South and South East Asia,
eastern Europe whereas prevalence is on the rise in the developed nations.
TRANSMISSION
Person-to-person transmission can occur through
? Sexual contact
? Injection drug use
? Contaminated blood products
? Mother-child transmission
? Occupational exposure
PATHOGENESIS AND PROGRESSION OF DISEASE
HIV is a member of the lentivirus family of retroviruses. HIV
appears   as   spherical   particles   that   are   approximately   110   nm   in
diameter,  with knoblike  projections  on  the  surface  of  the  virus  and
a  cone-shaped  viral core. 18    The  genome  is   organized  into  three
major  regions  (gag,  pol,  and env)  and  has  six  regulatory  genes  that
are  vital  for  its  life  cycle,  and  the  subsequent  exposure  of  the  other
HIV  envelope protein, gp41.
After the fusion of the viral and cellular membranes, the viral
capsid enters the cell and the HIV reverse transcriptase enzyme converts
the single- stranded  HIV  RNA  into  a  double-stranded  DNA,  which
then   is   integrated  with   host   chromosome   by   the   viral   enzyme
integrase.   Cellular   enzymes  transcribe   the   provirus   into   mRNA
which  is  then  translated  into  the structural proteins or which serve as
genomic RNA for progeny virus. Viral replication  involve  both  the
assembly  of   the  viral   particles,   with  each  viral  core  incorporating
two  copies  of  the  viral  RNA  genome,  and  the  budding and  release
of  the  virus  from  the  cell  surface  mediated  by  HIV  protease
enzyme.
Disease Progression
Shortly after acute HIV infection, HIV begins to preferentially
destroy HIV-directed  CD4+  helper  T  cells;  this  process  impairs  the
critical interaction between host CD4+ T cells and CD8+ T cells and thus
weakens the  host  CTL  response.  HIV extensively seeds lymphoid
organs and the central nervous system.  As a result, the infection persists,
and continued rounds of replication lead to the gradual depletion of all
CD4+ T cells.  At the same time, a subset of activated, HIV-infected
CD4+ T cells returns to a quiescent state, remains latently infected.19
The  CD4+  T  cell  count provides  an  accurate  way  to  assess
the  current  immunologic  status.  The plasma HIV RNA level is a strong
independent predictor of the progression to  AIDS  in  untreated  HIV-
infected  persons20 .    In  essence,   the  higher  the HIV RNA level,  the
more rapidly the disease will progress.
Clinical Features
Primary Infection
Primary   infection   is   symptomatic   in   70-80%   of   infected
individuals  and usually  occurs  2-4  weeks  after  exposure.  The  major
clinical  manifestations are  fever (seen in 80% to 90% of patients),
fatigue  (70%  to  90%),  rash  (40%  to   80%),   headache(32%   to   70%),
lymphadenopathy  (40%  to  70%), pharyngitis  (50%  to  70%),  and
myalgias  or   arthralgias  (50%  to  70%).21 Acute HIV illness typically
persists for less than 14 days, but some patients have had illnesses that
have extended for longer than 10 weeks. The  appearance  of  specific
anti-HIV  antibodies  in serum  takes  place later  3-12  weeks  later,
although  very  rarely  seroconversion  may  take  place after 3 months.
Asymptomatic stage-clinical latency
The   median   time   of   this   stage   is   about   10   years   during
which   HIV  replication   is   ongoing   and   progressive.   The   rate   of
disease  progression  is directly  correlated  to  with  HIV  RNA  levels  as
stated  above.  Long-term nonprogressors show little, if any, decline in
CD4+ T cell counts. During the asymptomatic  phase,  the  average  rate
of  CD4+  T  cell  decline  is  50/µL  per year.    When  the  CD4+  T  cell
count  falls  below  200/µL,  the  resulting immunodeficiency leads to
symptomatic disease.
Symptomatic disease-AIDS
Acquired immunodeficiency syndrome (category c disease) is
defined by the development of specified opportunistic infections, tumors
etc.
Common AIDS – Defining Conditions
? Oesophageal candidiasis
? Cryptococcal  meningitis
? Chronic cryptosporidial diarrhea
? CMV retinitis
? Chronic mucocutaneous herpes simplex
? Disseminated mycobacterium avium intercellulare
? Military or extrapulmonary tuberculosis
? Pneumocystis pneumonia
? Cerebral toxoplasmosis
? Kaposi’s sarcoma
? HIV encephalopathy/PML
? lymphoma
The  listed  AIDS  defining  conditions  are  as  per  revised  CDC
classification   (1993)   which   categorizes   persons   on   the   basis   of
clinical  conditions  and  CD4+  T-lymphocyte  counts22    For  children
less   than   13  years   of   age,   there   is   a   modified   and   revised
classification  system  for  HIV infection.  The World  Health
Organization   (WHO)   has   also   published   a  staging  system  for  HIV
infection. The WHO classification is an approach for use in resource-
limited settings and is widely used in Africa and Asia.
WHO staging of HIV infection
Clinical group-I
? Acute HIV infection
? PGL
? Asymptomatic
? Normal activity
Clinical group-II (Early stage disease)
? Weight loss<10%
? Muco-cutaneous problem
? Herpes zoster
? Recurrent URI
? Normal activity
Clinical group-III (Intermediate disease)
? Weight loss<10%
? Chronic diarrhea
? Prolonged fever 1 month
? Oral candidiasis
? Oral hairy leukoplakia
? Pulmonary tuberculosis
? Severe bacterial infection
? Bed ridden < 50% of day (previous month)
Clinical group-IV (Late stage disease)
? Definitive or presumptive diagnosis of AIDS
? Bed ridden > 50% of day (previous month)
The diagnosis of HIV infection depends upon the demonstration of
antibodies  to  HIV  and  /  or  the  direct  detection  of  HIV  or  one  of
its components.
Diagnosis
The  standard  screening  test  of  HIV  infection  is  the  ELISA,
also referred  to  as  enzyme  immunoassay  (EIA).  This  solid  –  phase
assay  is  an extremely good screening test with a sensitivity of >99.5%.
Most diagnostic laboratories use a commercial EIA kit that contains
antigens from both HIV -1 and HIV -2 and thus are able to detect either.
These  kits  use  both  natural  and   recombinant   antigens   and   are
continuously  updated  to  increase  their sensitivity  to  newly  discovered
species,  such  as  group  O  viruses.  EIA  tests are generally scored as
positive (highly reactive), negative (nonreactive), or indeterminate
(partially  reactive).  While  the  EIA  is  an  extremely  sensitive test, it is
not optimal with regard to specificity.
The most commonly used  confirmatory  test  is  the  western  blot.
This assay  takes  advantage  of  the  fact  that  multiple  HIV  antigens  of
different, well  –  characterized  molecular  weight  elicit  the  production
of  specific antibodies.  These  antigens  can  be  separated  on  the  basis
of  molecular weight, and antibodies to each component can be detected
as discrete bands on the western blot23.
 A negative western blot is one in which no bands are present at
molecular weights corresponding to HIV gene products. While  the
western  blot  is  an  excellent  confirmatory  test  for  HIV infection  in
patients  with  a  positive  or  indeterminate  EIA,  it  is  a  poor screening
test. Among individuals with a negative EIA and PCR for HIV, 20 – 30
% may show one or  more bands on western blot.  While these bands are
usually faint and represent cross-reactivity, their presence creates a
situation in which other diagnostic modalities (such as DNA PCR, RNA
PCR,  RNA  assay,  or  p24  antigen  capture)  must  be  employed  to  ensure
that the bands do not indicate early HIV infection.
The CD4+ T cell count is the laboratory test generally accepted as
the best  indicator  of  the  immediate  state  of  immunologic
competence   of   the  patient   with   HIV  infection.   This   measurement,
which  is  the  product  of  the percent  of  CD4+  T  cells  (determined
by  flow  cytometry)  and  the  total lymphocyte  count  (determined  by
WBC  and  differential  percent)  has  been shown to correlate very well
with the level of immunologic competence.
Patients  with  HIV  infection  should  have  CD4  +   T   cell
measurements performed at the time of diagnosis and every 3 to 6 months
thereafter.  More  frequent   measurements   should   be   made   if   a
declining  trend  is  noted. According  to  most  guidelines,  a  CD4+  T
cell   count   <350   /µL   is   an  indication   of   initiating   antiretroviral
therapy,  and  a  decline  in  CD4+  T  cell count of > 25% is an indication
for considering a change in therapy.
ANTIRETROVIRAL THERAPY
The  development  of  antiretroviral  therapy  has  been  one  of  the
most dramatic progressions in the history of medicine. Few other areas
have  been  subject  to   such  fast  and  short-lived   trends.   Since   the
introduction   of  zidovudine   as   monotherapy   in   1987,   the   treatment
options  have  grown rapidly.
Research   has   unleashed   an   array   of   drugs   in   each   of   the
class  of drugs and newer classes of drugs are fast coming upon the
horizon.
Currently, four different classes of medications, target HIV:
(1) nucleoside reverse transcriptase inhibitors (NRTIs)—
abacavir, didanosine, emtricitabine, lamivudine, stavudine,
tenofovir disoproxil fumarate (tenofovir-DF), zalcitabine, and
zidovudine;
(2) nonnucleoside reverse transcriptase inhibitors (NNRTIs)—
delavirdine, efavirenz, and nevirapine;
(3) protease inhibitors
atazanavir, fosamprenavir, indinavir, lopinavir plus ritonavir,
nelfinavir, ritonavir and saquinavir
(4) fusion inhibitors
Enfuvirtide
Newer  drugs  and  classes  of  drugs  that  have  or  about  to  join
these  popular drugs are
New nucleoside analogs
? Elvucitabine, Nicavir, Racivir, Stampidine
New NNRTIs
? Etravirine, Rilpivirine
New protease inhibitors (PIs)
? Darunavir,  Brecanavir
Coreceptor antagonists - CCR5 antagonists.(30)
? Maraviroc, Vicriviroc
Integrase inhibitors
? Raltegravir24
Other drugs in the pipeline are –
? Maturation inhibitors
? Fusion inhibitors
? Attachment inhibitors
? Entry inhibitors.
Mechanism of action
The NRTIs—also known as nucleoside analogues—structurally
resemble the human nucleosides that HIV uses to make viral DNA. The
HIV reverse  transcriptase  enzyme  can  mistakenly  incorporate  the
synthetic  nucleoside   analogue   into   the   elongating   strand   of   viral
DNA  during  the reverse  transcriptase  process;  once  incorporated  into
viral   DNA,   the  nucleoside   analogues   act   as   chain   terminators
because  they  lack  the  3? hydroxyl group required for chain elongation.
The   NNRTIs   do   not   act   as   chain   terminators;   rather,   they
directly inhibit the proper functioning of the reverse transcriptase
enzyme.
The  HIV  protease  inhibitors  selectively  bind  to  HIV  protease
and  prevent   this   enzyme   from   performing   its   normal   function   of
cleaving  viral polyprotein precursors into individual functional proteins.
The fusion inhibitor works by binding to the gp41 envelope protein
of HIV to prevent it from mediating fusion of the viral and cell membrane
HAART – IT’S IMPLICATIONS
The   term   ‘highly   active   antiretroviral   therapy’   gained
widespread acceptance  since  1996  when  the  new  class  of  protease
inhibitors  were approved for use. Since then HAART has maintained
itself as the first line of defence  against  HIV  infection.  Traditionally
HAART  consists  of combination  of  three  or  more  drugs  in  any  of
the  following class,  not necessarily in the same order:
NRTI + NRTI + NRTI / NNRTI / PI
In the earlier phase HAART was shown to reduce, between 1994
and  1998,  the  incidence  of  AIDS  in  Europe  from  30.7  to  2.5  per
100  patient years 25 which was replicated elsewhere.
In 1997, the FDA published the first warning about the
development of diabetes  mellitus  associated  with  the  use  of  PIs 26.
Realization about lipodystrophy, a new term, followed by
mitochondrial toxicity 27 reinforced  the   dictum:   all   effective   drugs
have  side  effects.  The  initial  euphoria  over eradication of viral load
with HAART has turned bleak with HIV remaining detectable in latently
infected cells, even after long-term suppression and the most recent
estimate for eradication of these cells standing at 73.3 years28 This has led
us to coexist with the spectrum of dramatic improvement in  the  standard
of   living   standard   of   HIV   infected  individuals   on   one   hand  and
hitherto  unheard  of  toxicities  of  associated  with  daily  consumption
of  loads  of  drugs  on  a  long  term  basis.  Treatment  of  HIV  infection  has
become a complicated balancing act between the benefits of durable HIV
suppression and the risks of drug toxicity
Thyroid
The  thyroid   is   one   of   the   largest   endocrine   glands   in   the
body, weighing approximately  15  to  20  g.  The  presentation  of
thyroid  conditions can  range  from  clinically  obvious  to  clinically
silent.  Their consequences can be widespread and serious, even life
threatening. Persons of both sex and any  age  can  be  affected,  although
almost  all  forms  of  thyroid  disease  are more frequent in women than
in men, and many thyroid ailments increase in frequency  with  age.
The thyroid dysfunction is simply classified  as hypothyroidism,
hyperthyroidism,  sub  clinical  hypothyroidism  and  sub clinical
hyperthyroidism  depending  upon  the  TSH  and  thyroid  hormone
levels.
Clinical status TSH
level
Thyroid
hormone
Normal Normal Normal
Hypothyroid High Low
Hyperthyroid Low High
Sub clinical Hypothyroid High Normal
Sub clinical Hyperthyroid low Normal
Hypothyroidism
Hypothyroidism   is   the   condition   resulting  from   lack  of   the
effects  of the  thyroid  hormone  on  body  tissues.  Hypothyroidism is a
common condition. 29&30 The overall incidence in the population is
approximately 1% to 2 %.31&32 In both sexes, the incidence increases
during and after middle life.33  The  serum  TSH  levels  are  more  than
10mU/L  and  associated  with low  values  of  thyroid  hormones.  Florid
hypothyroidism can be diagnosed clinically.
The symptoms of hypothyroidism are:
? Tiredness, weakness
? Dry skin
? Feeling cold
? Hair loss
? Difficulty in concentrating and poor memory
? Constipation
? Weight gain with poor appetite
? Dyspnea
? Hoarse voice
? Menorrhagia (Later amenorrhea)
? Paraesthesia
? Impaired hearing
The signs of hypothyroidism are as follows
? Dry coarse skin
? Cool peripheral extremities
? Puffy face, hands and feet (myxedema)
? Diffuse alopecia
? Bradycardia
? Peripheral edema
? Delayed tendon reflex relaxation
? Carpal tunnel syndrome
? Serous cavity effusions.
SUBCLINICAL HYPOTHYROIDISM
The term subclinical hypothyroidism designates a situation in
which an asymptomatic patient has a low-normal FT4 but a slightly
elevated serum TSH level.   Other  terms  for   this   condition  are  mild
hypothyroidism, preclinical  hypothyroidism,  biochemical
hypothyroidism,  and  decreased thyroid reserve. The TSH elevation in
such patients is modest, even a high normal  serum  TSH  level  (e.g.,  3.0
µU/L)  may  reflect  very  mild  thyroid dysfunction,  particularly  in  a
patient  who  has  other  clinical  or  laboratory features  of  autoimmune
thyroiditis.
As  a  result,  some  authorities  have recommended  lowering  the
TSH   assay’s   upper   limit   of   normal   to   2.5  µU/L34 The  values
typically between 4.25 and 10 µU/L. 35  associated with normal total or
free T4 and T3 levels constitute subclinical hypothyroidism as  stated  in
the   latest   consensus   statement   by   the   American   Association   of
Clinical   Endocrinologists,   the   American   Thyroid   Association,   and
The Endocrine Society.
HYPERTHYROIDISM
Hyperthyroidism  is  the  condition  resulting  from  the  effect  of
excessive amounts of  thyroid  hormones in  the body  tissues.
Thyrotoxicosis is a synonym.  Graves’s disease is the most common
cause of hyperthyroidism. Approximately 0.5% to 1% of the population
suffers from hyperthyroidism.  The TSH levels are suppressed, usually <
0.1  mU/L  and associated with high levels of thyroid hormones.
The symptoms of hyperthyroidism are as follows:
? Hyperactivity, irritability, dysphoria.
? Heat intolerance and sweating
? Palpitations
? Fatigue and weakness
? Weight loss with increased appetite
? Diarrhoea
? Polyuria
? Oligomenorrhea, loss of libido
The signs of hyperthyroidism are as follows:
? Tachycardia; Atrial fibrillation in the elderly
? Tremors
? Goitre
? Warm, moist skin
? Muscle weakness, proximal myopathy
? Lid retraction or lid lag
? Gynaecomastia
SUB CLINICAL HYPERTHYROIDISM
Sub clinical hyperthyroidism is defined as low serum TSH levels
(0.1mU/l to 0.4mU/L) associated with normal free T4 and free T3
levels.36 Sub clinical hyperthyroidism is much less common than sub
clinical hypothyroidism. The prevalence is about 2%; it is more common
in women, blacks, and the elderly.
NON THYROIDAL ILLNESS
Alteration in serum thyroid hormones occurs in wide variety of
illness which predominantly affects the T3 level and no intrinsic disease
of thyroid gland is detected. It is variously termed as Low T3 syndrome,
Sick euthryoid syndrome, Non thyroidal illness syndrome and Thyroid
hormone adaptation syndrome.
This syndrome occurs in wide variety of illness as follows:
? Acute critical illness and febrile illness such as infections,
myocardial infarction etc.
? Injuries such as burns, trauma, etc.
? Surgery
? Fasting
? Diabetes mellitus
? Liver disease
? Renal disease
? Ketogenic diet
? Drugs such as glucocorticoids, dopamine, phenytoin and beta
blockers
? Malignancy
? Psychiatric illness
In   non   thyroidal   illness   state,   initially   there   is   decrease   in
serum  T3 level,  both  total  and  free  T3  (FT3).  This is associated with
increase in reverse T3 (rT3).
As illness progresses, there is decrease in serum T4 also, a state
called "Low T3, T4 syndrome". Although total T4 level decreases, the
free T4 (FT4) remains normal or slightly reduced. In spite of this reduced
T3 and T4 level,  serum  TSH  level  remains  normal  or  reduced,  by
which  it  is differentiated  from  primary  hypothyroidism.  However,
many studies have showed slight elevation of TSH level in Non thyroidal
illness in the absence of hypothyroidism.
THYROID FUNCTION TESTS
TSH  is  released  from  the  anterior  pituitary  under  positive
regulation from TSH-releasing hormone (which is released from the
hypothalamus) and negative  feedback  from  the  thyroid  hormones  tri-
iodothyronine  (T3)  and thyroxine  (T4).  Most clinical  laboratories use
TSH assays  that have  a  limit of  detection  of  <0.02  mU/L  and  that,
therefore,are   suitable   for   identifying  the  majority  of  cases  of  both
hypothyroidism and hyperthyroidism37.
T4  is  secreted  from  thyroid  follicular  cells  during  hydrolysis
of  the thyroid hormone storage glycoprotein, thyroglobulin. In serum,
99.9% of T4 is bound to thyroxine-binding globulin and other proteins,
although only the free hormone is available for cell uptake and is thus
biologically active. Because  of  the  extensive  protein  binding,  total  T4
levels  may  correlate poorly  with  disease  states;  for  example,
estrogen  use,  pregnancy,  acute hepatitis,  and  certain  genetic
abnormalities  are  associated  with  increased thyroxine-binding globulin
concentrations and may result in a T4 level that is  misleadingly  elevated.
Conversely,   in   clinical   situations   those   are  associated   with   low
thyroxine-binding  globulin  concentrations. Current guidelines
recommend  measuring   the   T4   level   only   after   the   TSH  level   is
found   to   be   abnormal   or   if   central   hypothyroidism   or   thyroid
hormone resistance is suspected 38.
Most T3 is produced by systemic 5_-deiodination of T4;only 20%
of T3 is released from the thyroid . A second T4 deiodination pathway
leads to the  production  of  an  inactive  hormone,  3,3_,5_-
triiodothyronine  or  reverse T3.  Although  T3  is  the  most  active  form
of  thyroid  hormone,  the  clinical utility of measuring T3 is limited to a
few  situations.  In  patients  with  a   low   TSH   level,   T3   should   be
measured
(1)   to   evaluate   for   isolated  elevation  of  the  T3  level  (i.e.,  T3
toxicosis),
(2)  to determine the severity of thyroid disease, or
(3) to monitor response to antithyroid therapy. However in  patients
with   an   elevated   TSH   level,   T3   concentrations   are   initially
maintained in the normal range by increased peripheral conversion of T4
to T3; therefore, this measurement has reduced sensitivity for the
diagnosis of hypothyroidism39.
HIV AND THYROID
While baseline thyroid profiles in HIV infection may remain
normal, it  becomes  abnormal  during  the  course  of  disease.  Among
individuals infected with HIV, 1%–2% experience overt thyroid disease,
and  35%  may  have   subtle   abnormalities   in   thyroid   function   test
findings.36
In  patients with  advanced  HIV disease,  a  variety  of  systemic
opportunistic  conditions that infect or infiltrate the thyroid can decrease
or increase T4 secretion40 Cases  of  thyroiditis  have  been  reported  in
association  with  Pneumocystis jiroveci infection, Cryptococcus
neoformans infection, visceral leishmaniasis,  CMV  infection  and
suppurative  bacterial  infection  of  the thyroid41,42,43&44.   These
infiltrating conditions lead to destructive thyroiditis, which  is  usually
accompanied  by  neck  pain,  thyroid  enlargement,  and increased
thyroxine release. After treatment of the infection, thyroid function can
return to normal, but it should be closely monitored until it does so. In
addition, both lymphoma and Kaposi sarcoma can infiltrate the thyroid
and impair function.  Less requently, hypothalamic  –  pituitary  failure
due  to central nervous system infections is involved. Symptomatic
thyroid infection or infiltration has always been uncommon, and in
countries where HAART is available, it has become extremely rare.
 A  retrospective  and  prospective  study,  from  India,  of  thyroids
obtained   at   autopsy   found   high   incidence   (35%)   of   abnormal
thyroids  and tuberculosis was the predominant finding in these
specimens. 45
 Overt hypothyroidism is common both among the general
population, in  which  0.3%46of  persons  are  affected,  and  among  HIV-
infected individuals, among whom small studies have reported a
prevalence of 0%–2.6%.47&48
Low  FT4  levels  with  concurrent  normal  TSH  levels  are  found
frequently  among  HIV-infected  individuals,  with  a  reported
prevalence  of 1.3%–6.8%36,47&49 An even higher prevalence was reported
among  children  in   a   paediatric   study   in   which   16   (31%)   of   52
children,  all  of  whom  were receiving HAART, had this abnormality50.
Among   patients   with   HIV   infection   and   subclincal
hypothyroidism, anti-thyroid  peroxidase  antibodies  are  rarely
identified,  suggesting  that  the etiology may not be autoimmune 51.
Among   HIV-infected   populations,   the   highest   frequency   of
nonthyroidal illness was reported among patients with terminal AIDS
before the  HAART  era,  with  as  many  as  16%  of  patients  affected.
During severe  illness,  including  advanced  AIDS,  5_-deiodination  of
T4  declines, leading  to  decreased  T3  production  and  reverse  T3
metabolism,   and   5-deiodination  of  T4  to  inactive  reverse  T3  is
increased, creating a pattern of thyroid testing that suggests thyroid
dysfunction. This pattern, however, is a result  of  the  physiological
response  to  illness  and  not  a  result  of  abnormal thyroid function.
The most common thyroid function pattern during non thyroidal
illness is  reduced  T3  level,  elevated  reverse  T3  level,  variable  FT4
level,  and relatively  normal  or  decreased  TSH  level,  depending  on
the  severity  of illness, although a smaller increase in the reverse T3 level
has been observed among  patients   with  advanced  AIDS52    Because
chronic  HIV  infection itself  can  lead  to  nonthyroidal  illness,  this
diagnosis  should  always  be considered  for  patients  with  uncontrolled
HIV  infection  and  abnormal thyroid function test results.
Decreased CD4 cell count has been observed in patients who had
low FT3  levels  but  who  also  exhibited  weight  loss,  which  points  to
NTI53 Collazos et al. found a correlation between FT4 levels and CD4 cell
counts in  patients  treated  with  HAART.  They hypothesized  that  the
correlation might be mediated by cytokines, especially IL-2. The infusion
of  IL-2  in  asymptomatic  HIV-infected   patients   resulted   in   transient
increases  in  TSH, free thyroxine and CD4 cell counts 54
Experimental  studies on  the  influence  of  thyroid  hormones
on  the course  of  an  alloimmune  response  revealed  Murine  T3  and
T4  levels  were increased  a  few  days  after  the  immunization  of  mice
with  allogeneic lymphoid  cells.   Besides  in  vivo  treatment  with  T4
was  shown  to  increase alloantibody  titers  during  the  early  stages  of
alloimmunization  and  to enforce  lymphoid  proliferation  in  vitro  in  a
mixed  lymphocyte  reaction. Conversely,  lowering  thyroid  hormone
serum  levels  by  propylthiouracil treatment  negatively  modulates  the
humoral   and   cellular   alloimmune  responses.   The   evidence   here
points  to  the  existence  of  a  bidirectional communication between both
systems 55
Mean 24-hour TSH levels were increased in HIV patients,
associated with increased mean TSH pulse amplitude and TSH
responsiveness to TRH. No differences were observed between
asymptomatic HIV-seropositive and AIDS  patients.  In  conclusion,
there  is  a  hypothyroid-like  regulation  of  the pituitary-thyroid  axis  in
stable  HIV  infection,  which  differs  distinctly  from the  euthyroid  sick
syndrome  in  non-HIV-nonthyroidal  illnesses.  These changes in thyroid
hormones might be caused directly, as an HIV-associated impairment in
thyroid function, or indirectly, as an adaptation to counteract
hypermetabolism in HIV infection56
HAART AND THYROID
Several  complications  related  to  HAART  have  been  described,
including thyroid dysfunction, but the mechanism by which HAART
causes  these   alterations   remains   unknown,   even   if   is   probably
multifactorial  with the  HIV  infection  also  being  involved.  Regarding
thyroid  function  during HAART,  an  increased  prevalence  of  thyroid
function  parameter abnormalities have been reported by authors and
these refer in most cases to asymptomatic  patients,  in  particular
those  with subclinical hypothyroidism,  although  groups  of
patients  with  clinically evident  hyperthyroidism,  in  particular  Grave’s
disease,  have  also  been observed. In  some  cases  hyperthyroidism  has
been  considered  as  late manifestation  of  immune  reconstitution
caused   by   HAART.     Autoimmune  thyroiditis   has   also   been
implicated  in  the  development  of  subclinical hypothyroidism caused
by long term HAART.
Despite   the   autoimmune   etiology   of   most   cases   of
hypothyroidism, onset   of   Hashimoto  thyroiditis   does  not   appear  to
be  common  during HAART-associated  immune  reconstitution.
Stavudine  use,  however,  has been associated with subclincal
hypothyroidism in some, but not all, studies. The mechanisms underlying
this association are unclear and deserve further investigation.
One   postulated   hypothesis   is   that   the   retinoid   X   receptor-
selective ligand  suppresses  thyrotropin  secretion;  this  higher
prevalence  could  be related to the retinoid like effects of PIs. Another
hypothesis could be related to the lipodystrophy present in most of these
patients. Lipodystrophy could simulate a fasting situation leading to a fall
in the leptin level responsible for the suppression of the thyroid axis57
In adults, isolated low FT4 levels have been associated with receipt
of  didanosine,   stavudine,   and   ritonavir.  Higher   prevalence   was
reported among children in a paediatric study in which 16 (31%) of 52
children, all of whom were receiving HAART, had this abnormality.
Graves’  disease,  an  autoimmune  disease  that  leads  to  the  production
of   anti-TSH   receptor   antibodies,   is   the   leading   cause   of
hyperthyroidism both in the general population and in HIV infected
individuals.58 In persons with HIV infection, Graves’ disease may occur
after immune reconstitution from HAART. Graves’ disease is most
commonly diagnosed 12–36 months after HAART initiation.
The  conclusions  from  Iranian  study  was  different  from  others
which stated  that  age,  sex,  HAART,  mean  CD4-  cell  count,  duration
of  HIV infection,  HCV  co-infection,  and  opportunistic  infections
were  not significant  risk  factors  of  hypothyroidism  in  HIV-infected
patients.  The occurrence  of  hypothyroidism  may  be  related  to  other
factors  or  HIV infection itself. Therefore, hypothyroidism should be
considered in all HIV-infected patients59.
Beltran et al proved that none of the investigated mechanisms is
able to  explain  the  occurrence  of   hypothyroidism  in  HIV  patients
receiving highly  active  anti-retroviral  therapy  except  the  anti-
retroviral   treatment.   In  light   of   the   absence   of   autoimmunity,   the
normal  adenohypophysis  and thyroid responses to thyrotropin-releasing
hormone, central hypothyroidism is  suspected  and  could  explain  Low
T4  and  high  TSH  levels.  Underlying mechanisms need further
exploration.
Clinical syndromes involving decreased thyroid hormone levels
Condition TSH FT4 FT3 COMMENTS
Overt
hypothyroidism
?? ? ? May be associated
with anti TPO
Subclinical
hypothyrodism ? N N
More  common
during  HAART;
usually asymptomatic;
rarely
associated  with  anti-
TPO  in HIV- infected
patients; health
care providers
should  also  consider
recovery from
nonthyroidal illness
Isolated low FT4 N ? N More  common
during  HAART;
Usually asymptomatic
and of unclear
significance;  health
care providers  should
alsoconsider
nonthyroidal illness
Central
hypothyrodism ? ? ?
Very rare; when
symptoms  of
dysfunction  in  other
endocrine  systems
are  usually present
(pan-hypopituitarism
or hypothylamic
dysfunction)
Nonthyroidal
illness N/? N/
?
? Occurs  during  severe
acute  illnes or
cachexia  as  a  result
of  down-regulation of
conversion of T4 to
T3
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MATERIALS AND METHODS
Place of study : Department of Medicine,
Kilpauk Medical College and Hospital, Chennai
Collaborating
department
: ART centre and Department of Biochemistry,
Kilpauk Medical College
Duration of the study  : November 2009 - October 2010
Type of study : Cross sectional study
Conflict of Interest : None
Ethical Committee
Approval
: Obtained
Study population :
In the above mentioned study period, 110 patients were chosen
randomly who were either Pre ART HIV positive individuals (n=49) or
HIV patients on HAART (n=61) by strictly adhering to inclusion and
exclusion criteria.
Inclusion criteria
? All HIV infected patients both Pre ART and individuals
on HAART.
? Patients of more than 18 years
Exclusion criteria
? Patients less than 18 years of age
? Patients with  known thyroid dysfunction
? Patients on drugs known to cause thyroid dysfunction
? Pregnancy
? Severely ill patients
? Patients with renal and hepatic dysfunction
? Pituitary and  hypothalamic disorders
CONSENT
All patients gave written informed consent.
METHODOLOGY
Detailed history, symptoms and signs of thyroid dysfunction were
noted. History of medication, and anthropometric measurements like
height, weight, waist circumference were noted in a standard proforma.
All patients were completely examined and routine urine and blood
investigations were taken to rule out comorbid conditions. Patients were
staged in accordance to WHO guidelines and grouped accordingly.
The following investigations were done
? Thyroid profile (Free T4, FreeT 3 and TSH)
? Renal Function Test (Sugar, Urea, Creatinine, and Electrolytes)
? Liver  Function  Test  (S.Bilirubin,  SGOT,  SGPT,  SAP,  Total
Protein and Albumin)
? Complete  Blood  Count  (Total  Count,  Differential  Count,  ESR,
? Hemoglobin, PCV and Platelets)
? Electrocardiogram and Chest X-Ray – PA view
? CD4 Count
Detection of HIV infection
The detection of HIV infection was done by ELISA (Enzyme
Linked Immuno Sorbent Assay). The kit contains antigens for both HIV-
1 and HIV-2. These kits use both natural and recombinant antigens.
CD4 cell count
CD4 cell count was done  by  flow  cytometry.  The FACS count
method was used and laser principle technique was applied in it.
Thyroid Hormone Assay
The  thyroid   hormone   assay   (TSH  and   FT4)   were   done   by
Chemiluminescence  Immuno  Assay  (CLIA)  using  ADVIA  Centaur-
equipment.
DEFINITIONS- as per recommendations of consensus statement by the
American Association of Clinical Endocrinologists, the American
Thyroid Association, and The Endocrine Society. (15)
Euthyroidism
TSH :  0.34 - 4.25mU/L
FT 3 :  2.4   - 4.2 pg/ml
FT4 :  0.8   - 1.70 ng/dl
Sub clinical hypothyroidism
TSH :  4.25 - 10.0 mU/L
FT 3 :  2.4   -  4.2  pg/ml
FT4  :  0.8   -  1.70 ng/dl
Hypothyroidism
TSH :  > 10.0 mU/L
FT 3 : < 2.4 pg/ml
FT4 : < 0.80 ng/dl
Hyperthyroidism
TSH : < 0.1 mU/L
FT 3 : > 4.2 pg/ml
FT4 : > 1.70 ng/dl
Isolated low FT4
TSH :  0.34mU/L - 4.25mU/L
FT4 : < 0.80ng/dl
Isolated low FT 3
TSH :  0.34mU/L - 4.25mU/L
FT 3 : < 2.4 pg/ml
Statistical analysis
Statistical analysis was done by using windows SPSS software
(version 11.5). Chi square test was applied for significance. “P” value less
than 0.05 was considered as significant.
  RESULTS AND ANALYSIS
RESULTS
A total of 110 sero positives were taken as study group which
included 61 patients on HAART and 49 patients who were pre ART.
100 normal sero negative individuals with no history of thyroid
dysfunction were taken as control group.
? Majority of both the study and control groups were in the
age group of 25 - 36 years.
? Majority of thyroid dysfunction was also present in the same
age group mentioned above. (Table.1 and 1a )
Table. 1. Age distribution
Age distribution
Total< 25
years
25 - 35
years
36-45
years
> 46
years
HIV negative
individuals
30
(30%)
49
(49%)
17
(17%)
4
(4%)
100
HIV positive
individuals
13
(11.8%)
55
(50.5%)
35
(31.8%)
7
(6.4%)
110
Pre ART 7
(14.3%)
28
(57.1%)
13
(26.5%)
1
(2%)
49
(44.5%)
ART 6
(9.8%)
27
(44.3%)
22
(36.1%)
6
(9.8%)
61
(55.5%)
Table.1a. Abnormal Thyroid Function Test in HIV positive
individuals
< 25 years 25-35
years
36-45
years
> 46 years Total (41)
ART 3
(10.71%)
14
(50 %)
10
(35.4 %)
1
(3.57 %)
28
Pre
ART
2
(15.38 %)
7
(53.84 %)
3
(23.07 %)
1
(7.6 %)
13
Our study group had 54.5 % of male and 45.5 % o female. The
thyroid function tests were found to be abnormal in 58.54 % of males and
41.5 % of  females  (Table.2.).
Table.2. Gender distribution
Sex distribution
Total
Male Female
HIV negative
individuals
55
(55 %)
45
(45 %)
100
HIV positive
individuals
60
(54.5%)
50
(45.5 %)
110
Pre ART 24
(49 %)
25
(51 %)
49
(44.5%)
ART 36
(59 %)
25
(41%)
61
(55.5 %)
Housewives  (25.45%) and unskilled labourers (57.27%)
constituted the majority of the study group in both pre ART and ART
categories (Table.3.).
Table.3. Occupation
S.No. Occupation
Pre ART
individuals
ART
individuals
Total
1. Unskilled labourer 30
(61.22 %)
33
(54.09%)
63
2. Skilled labourer 4
(8.16 %)
8
(13.11%)
12
3. Lorry driver 3
(6.12%)
2
(3.28%)
5
4. Commercial  sex
worker
- 1
(1.64%)
1
5. Office worker - 1
(1.64%)
1
6. House wife 12
(24.49%)
16
(26.23%)
28
7. Businessman - - -
Heterosexual route was the most common mode of transmission of
HIV infection which is about 97 – 98 % (Table.4.).
Table. 4. Route of transmission
S.No.
Route of
transmission
Pre ART
individuals
ART individuals
1. Heterosexual 48 (97.9%) 59 (96.7%)
2. Homosexual 1(2.1%) 2(3.3%)
Mean duration of HIV infection was 2.3 years in study group and
the mean duration of patients with thyroid abnormality in HIV positive
individuals was 3.7 years.
Opportunistic infections were observed in 25 % of patients with
thyroid abnormality whereas 15 % in study group.
The commonest opportunistic infection was tuberculosis followed
by oral candidiasis and herpes zoster.
In study group 25 patients (22.7 %) had abnormal TSH level. Out
of which, 22 patients had  TSH in subclinical hypothyroid level and 3
patients had TSH in overt hypothyroid level. In sero negative group 2
persons (2 %) had abnormal TSH value in subclinical hypothyroid range.
Table.5. TSH analysis
TSH Total
Normal Abnormal
HIV negative
individuals
98
(98 %)
2
(2 %)
100
HIV positive
individuals
85
(77.3%)
25
(22.7 %)
110
Pre ART 40
(81.6 %)
9
(18.4 %)
49
(44.5%)
ART 45
(73.8 %)
16
(26.2 %)
61
(55.5 %)
Table.6. FT 3 analysis
FT 3
Total
Normal Abnormal
HIV negative
individuals
99
(99 %)
1
(1%)
100
HIV positive
individuals
98
(80.9 %)
12
(19.1 %)
110
Pre ART 47
(95.9)
2
(4.1)
49
(44.5%)
ART 51
(83.6%)
10
(16.4 %)
61
(55.5 %)
Table.7. FT 4 analysis
FT 4 value
Total
Normal Abnormal
HIV negative
individuals
99
(99 %)
1
(1%)
100
HIV positive
individuals
103
(93.6 %)
7
(6.4 %)
110
Pre ART
47
(95.9)
2
(4.1)
49
(44.5%)
ART
56
(91.8 %)
5
(8.2 %)
61
(55.5 %)
The most common thyroid dysfunction observed was subclinical
hypothyroidism both in ART and pre ART group with raised TSH and
normal range of FT 3 and FT 4.
Subclinical hypothyroidism was observed in 22 patients among
110 study group patients (Table.8)
Among them, 13 patients were from ART group and 9 patients
from Pre ART group.
Mean TSH range was higher in ART group 6.85 µIU / ml and in
pre ART group was 5.4 µIU / ml which is statistically significant. Three
patients in ART group were found to have overt hypothyroidism.
Three patients were having over hypothyroidism. Among them,
one patient have low FT 4 along with raised TSH and other two patients
had low FT 3 with raised TSH. (Table 5,8,9)
FT 3 abnormality was found in 19.1 % of study group. In pre ART
category it was 17 % and in ART category it was 83 % .
Isolated low FT 3 was the common FT 3 abnormality observed
which constituted about 92 %. One patient (8 %) had raised FT 3.
Mean FT 3 was 1.15 pg/dl in pre ART group and 1.3 pg/dl in ART
group. (Table 6,8,9)
FT 4 abnormality was found in 6.4 % study populations. Among
them, 71.43 % were in ART group and 28.57 % were in pre ART group.
Isolated low FT 4 was found in 85.7 % patients. One patient (14.3
%) had raised FT 4.
Mean FT 4 value was 0.42 ng/dl in ART group and 0.75 ng/ dl in
pre ART group. This was found to be statistically significant. (Table
7,8,9)
Table.8. Types of thyroid dysfunction in HIV positive individuals
Types of
abnormality
Total
cases
Pre ART ART
Subclinical
hypothyroidism
22
(53.6 %)
9
(69.2 %)
13
(46.43 %)
Overt hypothyroidism
3
(7.31 %)
-
3
(10.7 %)
Isolated low FT 3
9
(21.95 %)
2
(15.38 %)
7
(25 %)
High FT 3
1
(2.44 %)
-
1
(3.6 %)
Isolated low FT 4
5
(12.19 %)
2
(15.38 %)
3
(10.7 %)
High FT 4
1
(2.44 %)
-
1
(3.6 %)
Total 41 13 28
Table.9. Thyroid profile
Thyroid
profile
Normal
range
Pre ART ART
Mean value Mean value
TSH 0.34 – 4.25 5.40 6.85
FT 3 2.4 – 4.2 1.15 1.3
FT 4 0.80 – 1.70 0.75 0.42
Majority of FT 3, FT 4 and TSH abnormality was found in WHO
stage 3 and 4 in patients in ART group and in stage 2 and 3 in pre ART
group which was found statistically significant.
Table.10. WHO staging of HIV individuals on ART with Thyroid
Dysfunction
WHO
stage
TSH FT 3 FT 4
Total
Normal Abnormal Normal Abnormal Normal Abnormal
I 9
20%
2
12.5%
11
21.6%
- 11
19.6%
- 11
II 12
26.7%
4
25%
14
27.5%
2
20 %
16
28.57%
- 16
III 20
44.4%
6
37.5%
21
41.2%
5
50%
23
41.0%
3
60 %
26
IV 4
8.9%
4
25 %
5
9.8%
3
33 .3%
6
10.7 %
2
40%
8
Total 45
73.8%
16
26.2%
51
83.6%
10
16.4%
56
91.8
5
8.2%
61
Table.11. HIV individuals not on ART
WHO
stage
TSH FT 3 FT 4 Total
Normal Abnormal Normal Abnormal Normal Abnormal
I 17
42.5%
1
11.1%
18
38.3%
- 18
38.3%
- 18
II 20
50 %
6
66.6 %
26
55.3%
- 25
53.2%
1
50 %
26
III 3
7.5%
2
22.2%
3
6.4%
2
100%
4
8.5%
1
50 %
5
IV - - - - - - -
Total 40
81.6%
9
18.4%
47
95.9%
2
4.1%
47
95.9
2
 4.1%
49
Thyroid function abnormality was found commonly in patients
who were on the regimen AZT + 3 TC + NVP and raised FT 3 level was
found in patients who was on regimen AZT + 3 TC + EFV.
Table. 12. Thyroid function test in individuals on HAART
ART Abnormal Normal
TSH FT 3 FT 4
AZT + 3 TC + NVP 12
(31.52%)
7
(18.42%)
4
(10.52%)
16
(42.11%)
d4T + 3 TC + NVP 3
(23.08%)
1
(7.69%)
0(0)
8
(61.54%)
AZT + 3 TC + EFV 1
(10%)
2
(20%)
1
(10%)
6
(60%)
CD 4 count was < 200 in 36.1 %, 200-350 in 54.1 % under ART
group where as in pre ART group 32.65 % had CD 4 count 200- 350 and
67.35 % had CD 4 count  > 350.
Overt hypothyroidism was found mostly in patients with CD 4
count < 200 and subclinical hypothyroidism patients had CD 4 count
between 200 - 350.
Table. 13. CD 4 count in HIV positive individuals
CD count Pre ART ART
< 200 Nil
22
(36.1 %)
200 - 350
16
(32.65 %)
33
 (54.1 %)
> 350
33
(67.35 %)
6
9.8 %)
Total 49 61
Table. 14. Co-relation of CD 4 count with thyroid dysfunction
CD 4
count
Subclinical
hypothyroidism
Overt
hypothyroidism
? FT3 ? FT4
? FT
3
? FT 4
< 200
8
36.4 %
2
66.6%
5
55.5 %
2
40.0 %
1
100%
1
100 %
200 -
350
12
54.5 %
1
33.3 %
3
33.3 %
3
60.0%
- -
> 350
2
0.9 %
-
1
11.1%
- - -
  DISCUSSION
DISCUSSION
People with HIV appear to have greater likelihood of disorders of
thyroid. During HIV infections overt clinical manifestations are less
common whereas subtle changes in thyroid function are found more
commonly in several studies.
Grappin et al showed daily dose of both stavudine and lamuvidine
were related with presence of hypothyroidism.
Beltran et al found that use of stavudine and lower CD4 count were
associated with subclinical hypothyroidism.
Another  study  of  Beltran  et  al  showed  lower  levels  of  FT  3  with
stavudine.
Use of NNRTI especially efavirenz was showed to be a significant
predictor of hypothyroidism.
In JAPI 2009, an article by Gagan Jain showed significant thyroid
dysfunction in HIV individuals, where in 18 % and 20 % of the study
population showed ? FT 3 and      ? FT 4 respectively and 24% showed ?
TSH with significant P value < 0.05 and it had a direct co-relation with
low CD4 count.
Present study was undertaken based on the above observation, in
our hospital, Kilpauk Medical College Hospital, Chennai.
Age Distribution
Our study population consisted of 110 patients, chosen randomly
attending the ART center adhering to inclusion and exclusion criteria
(both pre ART = 49 and patients on ART=61)
The patients were divided into 4 groups as shown in Fig. 1.
The mean age group was between 25 – 35 years which constitutes
about 44.3 % patients on HAART and 57.1 % of patients not on ART.
The study group was compared with 100 normal patients selected
randomly with no previous thyroid dysfunction.
The comparison between these two groups the HIV positive
individuals and HIV negative individuals was statistically significant with
p value < 0.05 and chi square13.67.
Majority of abnormal thyroid function test was found in age group
between 25- 35 years which constitutes 50 % of patients on HAART and
53.84 % of patients not on ART.
Gender Distribution
In  our  study  the  overall  male  population  was  more  than
their  female counterpart,  with  a  sex  ratio  of  1.2 in  favour  of  males.
The prevalence of thyroid dysfunction was found to be more in male than
female. There was no statistical correlation between gender and thyroid
dysfunction. There  are  no  studies  available  that  has  data  available
on  thyroid dysfunction and gender influence in HIV patients on HAART.
The gender distribution demonstrated 60 (54.4%) and 50 females
(45.5%) in our study population and thyroid abnormalities was found in
43. 3 % HIV +ve in males and 22 % HIV +ve females individuals. This
was compared with normal population and was found to be statistically
insignificant with p value 0.29
Occupation
In our study group unskilled labours and housewives constituted
majority of the population 57.27% and 25.45% respectively,10.91 were
skilled ,CSW -0.9   lorry drivers - 4.5% office workers 0.9% statistically
the nature of work was not related significantly thyroid dysfunction.
Route of transmission
Most of the study population and heterosexual behaviour in our
study group 97.27%.
Duration of Infection
Mean duration of HIV infection was 2.3 years in study group and
the mean duration of patients with thyroid abnormality in HIV positive
individuals was 3.7 years.
Opportunistic infection
Opportunistic infections were observed in 25 % of patients with
thyroid abnormality whereas 15 % in study group. The commonest
opportunistic infection was tuberculosis followed by oral candidiasis and
herpes zoster.
Symptoms and signs
One 40 years old female patient on ART had thyroid enlargement.
Thyroid dysfunction
TSH was found to be abnormal in 25 patients among 110  study
group population which constitute about 22.7%.Among 25 patients 16
were  patients  on  HAART  and  9  were  pre  ART  individuals  which  was
about 26.2% and 18.4% respectively. All the 25 patients had elevated
TSH values.
In the normal population 2% had elevated TSH value.
Range of TSH
In ART - 4.464 – 11.371 with mean of 6.850
In  pre ART  - 4.977 – 6.423  with mean value of 5..4
The TSH abnormality was found to be stsistically significant
with p value < 0.05.
FT 3 analysis
FT3 value was found to be abnormal in 12 patients among 110
patients which constitutes 10.9% .Among 12 patients 10 were on HAART
and 2 were pre ART with constitutes 16.4% and 4.1% respectively.
FT3 was elevated in 1 patient who was on HAART and none in pre
ART.
Isolated ?FT3 was found in 7 patients on HAART and 2 patients in
pre  ART.2  paints  on  HAART  with  ? FT3  was  associated  with  elevated
TSH. This was found to be statistically significant with p vaiue < 0.05.
FT4 analysis
FT4 value was found to be abnormal in 7 HIV positive individuals
among 110 patients who constitute 6.4%.5 out of the 7 patients were on
HAART and 2 were in pre ART group which constitutes 8.2% and 4.1%
respectively.
Isolated FT4was elevated in 1 patient on HAART
Isolated ?FT4 was found in 3 individuals on HAART and 2
patients in pre ART group.1 patient with ?FT4 was associated with
elevated TSH.
WHO staging
Of the  110  study  population  61  patients  were  on  HAART and  49
patients  were in the pre ART group.
Of the 61 patients in the HAART group
? 11 patients ( 18.03%) belong to WHO stage I
? 16 patients 26.23% belong to WHO stage II
? 26 patients 42.62% belong to WHO stage III
? 8 patients 13.11% belong to WHO stage IV
Majority of  the FT3, FT4 and TSH abnormality was found to be in
WHO stage III and IV that is TSH abnormality was found in 37.5% in
stage III and 25%in stage IV.
FT3 ABNORMALITTY
? 50% in stage III
? 33% in stage IV
FT4 ABNORMALITY
? 60% -stage III
? 40%-stage IV
Of the 49 pre ART individuals
? 18 patients (36.73%) were in WHO stage I
? 26 patients (53.06%) were in WHO stage II
? 5 patients (10.2%) were in WHO stage III
? None in stage IV
Majority of FT 3, FT4 and TSH abnormality was found in stage II and III
TSH abnormality - 55.5 % stage II
FT 3 abnormality – 100 % stage III
FT 4 abnormality – 50 % ach in stage II & III
CD 4 count
CD 4 count was < 200 in 36.1 %, 200-350 in 54.1 % under ART
group where as in pre ART group 32.65 % had CD 4 count 200- 350 and
67.35 % had CD 4 count  > 350.
Overt hypothyroidism was found mostly in patients with CD 4
count < 200 and subclinical hypothyroidism patients had CD 4 count
between 200 - 350.
Drugs and thyroid function test
Of the 61 patients who were on HAART. 39 patients (64 %) were
in the (a) Zidovidine + Stavudine  +  Nivarapin group.
Out of this 39 patients (64 %), 12 patients (31.52%) had SH
abnormality. 7 patients (18.42%) had FT 3 abnormality, 4 patients
(10.52%) had FT 4 abnormality.
16 patients (42.11 %) had normal TFT
12 patients (19.67 %) were under (b) stavudine + lamivudine +
Nivarapine
Of these 12 patients, 3 patients (23.08 %) had TSH abnormality
1 patient (7.67%) had FT 3 abnormality
No FT 4 abnormality was detected.
8 patients (61.54 %) had normal TFT
(C) 10 patients (16.39 %) were in the zidovidine + stamivudine +
efavirenz therapy
1 patients (10 %) had TSH abnormality
2 patients (20 %) had FT 3 abnormality
1 patients (10 % ) had FT 4 abnormality
6 patients (60%) had normal TFT
  CONCLUSION
CONCLUSION
? Thyroid abnormality especially subclinical hypothyroidism is more
prevalent in HIV positive individuals compared to normal sero
negative individuals.
? All forms of thyroid dysfunction were observed more in patients on
HAART than in pre ART individuals.
? Thyroid abnormality was found more in males in our study group.
? Majority of thyroid abnormality was found in the age group of 25 –
35 years.
? There was significant inverse correlation between CD 4 count and
thyroid abnormalities. Decline in CD 4 count was associated with
increased incidence of thyroid abnormalities.
? There was significant correlation between duration of HIV
infection and prevalence of thyroid dysfunction which was found
more in patients with longer duration of HIV infections.
? Thyroid abnormality was found more in advanced stage of disease
who were in  WHO stage III and IV.
? Heterosexual route was the common route of transmission.
? Tuberculosis was the most common opportunistic infection.
? Thyroid abnormality especially subclinical hypothyroidism was
common in the HAART group under the Ziduvidine + stamivudine
+ nevarapine regimen.
? Screening   of   thyroid   parameters   is   warranted   in   this
population  in  view  of increasing prevalence in the study
population.
LIMITATIONS
? The sample size was small
? Thyroid antibodies were not measured
? Follow up study was not done. So incidence of thyroid
abnormalities with previous normal function could not be studied.
  ANNEXURES
PROFORMA
NAME HOSTITAL No: SERIAL NO
AGE HEIGHT WHO
SEX WEIGHT EDUCATION
OCCUPATION BMI ADDRESS
MARITAL STATUS :
SEXUAL EXPOSURE :
OTHER RISK  FACTORS :
PARTNER’S HIV STATUS :
DURATION OF HIV INFECTION :
AGE AT FIRST SEXUAL
EXPOSURE
:
RECENT EXTRA MARITAL
EXPOSURE
:
PREVIOUS STD’S :
PRESENT STD’S :
SMOKING :
ALCOHOL :
DM :
HT :
PREVIOUS THYROID
DYSFUNCTION
:
H/O ATT :
PRESENTING COMPLAINTS
TIREDNESS / WEAKNESS/
HYPERACTIVITY
: DRY SKIN:
COLD / HEAT INTOLERANCE HAIR LOSS:
DIFFICULTY IN
CONCENTRATION/POOR
MEMORY
: BOWEL
DISTURBANCES:
WEIGHT GAIN / LOSS
APPETITE
: DYSPNOEA:
HOARSENESS OF  VOICE : MENSTRUAL
PROBLEM:
PARESTHESIA :
EXAMINATION :
PALLOR :
JAUNDICE :
CYANOSIS :
THYROID SWELLING :
CLUBBING :
PEDAL EDEMA :
LYMPHADNOPAHY :
BP :
PR :
RR :
TEMPERATURE :
JVP :
OPPORTUNISTIC INFECTIONS :
CVS :
RS :
ABDOMEN :
CNS :
INVESIGATION
HEMOGRAM : CD 4 COUNT
HB  % :
TOTAL COUNT :
DIFFERENTIAL COUNT :
ESR :
PCV :
PLATELET COUNT :
ECG :
CHEST X RAY :
THYROID FUNTION TEST :
SERUM FREE T 3 :
SERUM FREE T 4 :
TSH :
RENAL FUNCTION TEST :
BLOOD SUGAR :
BLOOD UREA :
SERUM CREATININE :
SERUM ELECTROLYTES :
LIPID PROILE :
TOTAL CHOLESTROL :
TRIGLYCERIDES :
HDL :
LDL :
VLDL :
LIVER UNCTION TEST :
SERUM BILIRUBIN :
SGOT :
SGPT :
SAP :
TOTAL PROTEIN :
A/G RATIO :
ABBREVIATIONS
FT4/T4 : Free Thyroxine / Thyroxine
TSH : Thyroid Stimulating Hormone
FT3/T3 : Free Triodothyronine / Triodothyronine
HIV : Human Immuno deficiency Virus
AIDS : Acquired Immuno deficiency Syndrome
CD : Cluster differentiation
HAART/ART : Highly Active Anti Retroviral Therapy
PRE ART : HIV Patients not on Anti Retroviral Therapy
NTI : Non Thyroidal Illness
TO : Thyroid peroxidase
NRTI : Nucleoside Reverse Transcriptase Inhibitors
NNRTI : NonNucleoside Reverse Transcriptase Inhibitors
PI : Protease Inhibitor
S.No
Hospital
No. Age
Age
Group sex occupation WHO
route of
transmission
CD4
count
Duration
of illness BMI Opp.iinf ART
Throid
dusfunction
symptoms
Thyroid
enlargement TSH Ft3 Ft4
Lipid
profile RFT LFT
TSH -
AB/N
FT3
AB/N FT4AB/N
1 953 57 4  M 1 III 1 259 2 19 5 3 1  N 0.814 3.21 1.322 1  N N 0 0 0
2 2769 39 3  F 6 II 1 315 3 21 5 0 1  N 5.408 3.832 1.53 1  N N 1 0 0
3 773 26 2  M 1 II 1 324 2 21 1 1 1  N 1.895 2.621 0.86 1  N N 0 0 0
4 688 30 2  M 1  I 1 293 3 22 1 1 1  N 1.378 1.264 0.88 1  N N 0 1 0
5 1912 22 1  F 6  I 1 763 1 22 1 0 1  N 0.813 3.329 1.049 1  N N 0 0 0
6 972 46 4  M 2 II 1 288 3 20 1 0 1  N 2.344 3.819 0.779 1  N N 0 0 1
7 1594 33 2  M 1 III 1 356 1 22 5 0 1  N 5.159 3.6 1.549 1  N N 1 0 0
8 859 50 4  F 6 III 1 198 3 23 3 1 1  Y 8.679 1.3 0.84 1  N N 1 1 0
9 2672 45 3  F 6 III 1 483 1 23 1 0 1  N 4.032 2..927 0.956 1  N N 0 0 0
10 793 23 1  F 6 II 1 368 33 25 1 2 1  N 3.5 2.983 0.9 1  N N 0 0 0
11 186 35 2  F 6 II 1 458 2 19.6 1 0 1  N 2.325 3.319 1.198 1  N N 0 0 0
12 749 36 3  M 1 II 1 216 3 23 1 1 1  N 2.86 1.547 1.02 1  N N 0 1 0
13 756 44 3  F 6  I 1 786 3 24.2 5 0 1  N 1.41 3.9 1.297 1  N N 0 0 0
14 505 39 3  F 1 III 1 296 3 21 1 1 1  N 4.843 3.719 0.976 1  N N 1 0 0
15 1896 32 2  F 1  I 1 425 2 23.6 1 0 1  N 3.497 3.392 0.976 1  N N 0 0 0
16 1218 39 3  M 1 IV 1 173 6 19 5 3 1  N 3.968 2.82 1.821 1  N N 0 0 1
17 439 40 3  F 5 III 1 161 3 19.5 2 2 1  N 6.416 3.158 0.8 1  N N 1 0 0
18 281 35 2  F 6  I 1 706 3 23 1 0 1  N 1.113 2.941 0.89 1  N N 0 0 0
19 1206 32 2  M 1 II 1 182 3 21 1 1 1  N 4.421 3.162 0.894 1  N N 1 0 0
20 1449 20 1  F 1 II 1 356 1 21.7 1 0 1  N 3.258 3.472 0.881 1  N N 0 0 0
21 450 20 1  M 2 III 1 108 3 20 2 1 1  N 1.665 0.912 1.538 1  N N 0 1 0
22 1438 32 2  F 1 III 1 205 3 24.1 2 2 1  N 11.371 2.63 0.676 1  N N 1 0 1
23 1221 38 3  F 6 III 1 52 3 22 1 2 1  N 1.57 1.106 0.934 1  N N 0 1 0
24 1673 32 2  M 1  I 1 378 1 23.5 1 0 1  N 2.296 2.994 1.17 1  N N 0 0 0
25 740 24 1  F 6  I 1 282 2 22 1 1 1  N 0.669 3.572 1.14 1  N N 0 0 0
27 722 33 2  M 1 III 2 334 3 21 1 3 1  N 1.893 3.495 0.98 1  N N 0 0 0
28 2537 26 2  M 1  I 1 752 3 24.5 1 0 1  N 1.818 4.108 1.369 1  N N 0 0 0
29 622 46 4  M 2 II 1 238 3 19.5 1 1 1  N 1.702 3.248 1.094 1  N N 0 0 0
30 688 30 2  M 1 IV 1 39 3 19 1 1 1  N 4.436 4.198 1.236 1  N N 1 0 0
31 190 38 3  F 6 II 1 216 3 22 1 1 1  N 0.909 2.504 1.54 1  N N 0 0 0
32 2729 27 2  M 1  I 2 926 3 25.5 1 0 1  N 2.892 3.975 1.036 1  N N 0 0 0
33 930 39 3  M 1 III 1 121 3 18.6 2 1 1  N 7.464 2.714 1.465 1  N N 1 0 0
34 2553 35 2  M 1  I 1 454 2 19.7 1 0 1  N 1.884 3.344 1.15 1  N N 0 0 0
35 987 26 2  M 1 IV 1 282 3 18.5 1 1 1  N 9.405 3.352 0.984 1  N N 1 0 0
36 2533 26 2  M 1  I 1 254 2 20.1 1 0 1  N 3.803 3.63 1.1 1  N N 0 0 0
37 1174 36 3  M 1  I 1 843 2 23.2 1 1 1  N 2.04 3.564 1.308 1  N N 0 0 0
38 1218 38 3  M 1 II 1 274 1 21.2 5 0 1  N 4.977 3.64 0.965 1  N N 1 0 0
39 1015 33 2  M 1  I 1 293 2 19.4 1 1 1  N 5.168 2.717 0.963 1  N N 1 0 0
40 1249 29 2  M 1 II 1 322 1 23.4 1 0 1  N 5.642 2.82 0.945 1  N N 1 0 0
41 894 28 2  M 1 II 1 166 3 23.6 1 1 1  N 4.615 3.411 0.936 1  N N 1 0 0
42 2105 28 2  F 1 III 1 267 3 22.5 1 0 1  N 4.052 1.026 0.926 1  N N 0 1 0
43 792 28 2  M 1 III 1 198 3 22 1 1 1  N 2.25 3.158 0.33 1  N N 0 0 1
44 2102 24 1  M 1 III 1 215 2 22.6 1 0 1  N 2.062 1.326 1.05 1  N N 0 1 0
45 361 24 1  F 6 III 1 308 3 19 2 3 1  N 2.076 6.05 0.913 1  N N 0 1 0
46 1798 32 2  M 1 III 1 288 3 23.2 5 0 1  N 6.023 3.012 1.083 1  N N 1 0 0
47 368 47 4  M 1 III 1 394 3 24.2 1 1 1  N 3.368 4.132 1.552 1  N N 0 0 0
48 2509 29 2  F 6 II 1 386 3 24.2 1 0 1  N 3.896 3.521 1.05 1  N N 0 0 0
49 1113 34 2  M 1 IV 1 17 1 21.3 1 1 1  N 1.467 3.094 1.476 1  N N 0 0 0
50 1678 32 2  M 1  I 1 348 1 23.1 1 0 1  N 1.623 3.621 1.032 1  N N 0 0 0
51 954 39 3  M 1 IV 1 259 3 21.2 1 3 1  N 1.428 3.92 1.256 1  N N 0 0 0
52 2431 35 2  F 1  I 1 358 2 22.4 1 0 1  N 2.403 3.467 1.139 1  N N 0 0 0
53 1708 29 2  M 1 II 1 418 1 22.1 1 0 1  N 2.594 4.01 1.092 1  N N 0 0 0
54 754 40 3  M 1 IV 1 246 3 22 5 3 1  N 7.544 3.292 1.603 1  N N 1 0 0
55 2025 26 2  F 1 III 1 328 3 22.2 5 0 1  N 5.823 3.123 1.204 1  N N 1 0 0
56 345 50 4  M 1 IV 1 161 2 21.6 1 2 1  N 2.25 3.26 1.321 1  N N 0 0 0
57 1972 32 2  F 1 III 1 425 1 23.2 1 0 1  N 1.821 3.621 1.035 1  N N 0 0 0
58 349 42 3  M 1 IV 1 165 3 19.2 1 2 1  N 5.232 3.282 1.524 1  N N 1 0 0
59 1982 40 3  M 1 II 1 414 1 21.4 1 0 1  N 2.32 2.421 1.021 1  N N 0 0 0
60 1077 40 3  F 6 III 1 233 2 26.4 5 1 1  N 1.313 3.271 1.198 1  N N 0 0 0
61 2186 34 2  M 1 II 1 312 3 22.6 2 0 1  N 6.423 2.618 1.023 1  N N 1 0 0
62 211 39 3  M 1 II 1 789 3 24.2 1 0 1  N 2.701 3.64 1.168 1  N N 0 0 0
63 2329 35 2  F 6 II 1 486 1 19.8 1 0 1  N 2.621 2.521 0.986 1  N N 0 0 0
64 783 23 1  F 1 II 1 368 2 24.1 1 2 1  N 6.611 2.869 0.968 1  N N 1 0 0
65 2512 33 2  M 1 II 1 495 1 20.1 1 0 1  N 3.21 2.631 1.232 1  N N 0 0 0
66 255 36 3  M 1 II 1 310 1 23.2 1 0 1  N 5.811 4.091 0.968 1  N N 1 0 0
67 789 42 3  M 1 II 1 361 3 21.2 1 0 1  N 1.428 2.51 1.321 1  N N 0 0 0
68 247 37 3  F 6 III 1 128 3 18.6 1 2 1  N 0.908 3.36 1.42 1  N N 0 0 0
69 1452 28 2  M 1 II 1 328 2 23.4 1 0 1  N 3.214 3.21 1.231 1  N N 0 0 0
70 835 27 2  M 1 III 2 124 2 23.4 1 1 1  N 1.447 3.312 0.904 1  N N 0 0 0
71 1236 29 2  F 6 II 1 416 2 22.1 1 0 1  N 3.124 3.31 1.214 1  N N 0 0 0
72 1189 37 3  M 2 II 1 593 3 22.7 5 1 1  N 1.383 3.732 1.607 1  N N 0 0 0
73 1521 26 2  M 1 II 1 425 2 20.9 1 0 1  N 3.961 4.012 0.965 1  N N 0 0 0
74 1222 42 3  M 1  I 1 261 2 21 1 2 1  N 3.773 3.616 0.927 1  N N 0 0 0
75 2361 38 3  F 1  I 1 492 2 23.2 1 0 1  N 1.238 4.142 1.303 1  N N 0 0 0
76 2768 36 3  F 6 II 1 365 3 3.6 1 0 1  N 2.842 2.642 1.36 1  N N 0 0 0
77 708 36 3  M 1 III 1 183 2 22 1 1 1  N 3.057 2.653 1.684 1  N N 0 0 0
78 2142 25 1  M 1 II 1 326 2 22.4 1 0 1  N 2.682 2.682 0.928 1  N N 0 0 0
79 2576 25 1  F 6 IV 1 503 1 22 1 0 1  N 1.888 3.59 0.856 1  N N 0 0 0
80 2438 32 2  F 6 III 1 429 1 21.6 1 0 1  N 3.101 3.102 1.521 1  N N 0 0 0
81 828 35 2  F 6 II 1 247 2 23 1 1 1  N 2.403 3.467 1.139 1  N N 0 0 0
82 2416 41 3  F 6 II 1 395 2 22.2 1 0 1  N 1.428 2.51 1.321 1  N N 0 0 0
83 2553 35 2  F 6  I 1 1440 2 24.2 1 0 1  N 0.523 3.689 1.498 1  N N 0 0 0
84 692 30 2  M 1 III 1 284 3 22.1 1 1 1  N 3.206 3.152 1.32 1  N N 0 0 0
85 2220 50 4  M 1  I 1 282 2 21.6 1 0 1  N 2.447 3.592 1.39 1  N N 0 0 0
86 358 40 3  F 6 III 1 233 2 22.1 1 1 1  N 1.313 3.271 1.193 1  N N 0 0 0
87 1994 22 1  F 6 II 1 694 3 23.2 1 0 1  N 2.427 3.922 1.652 1  N N 0 0 0
88 2572 42 3  M 1 II 1 302 2 22.2 1 0 1  N 2.447 3.592 1.39 1  N N 0 0 0
89 2334 24 1  F 6  I 1 893 3 24.3 1 0 1  N 1.238 4.146 1.303 1  N N 0 0 0
90 2418 40 3  M 1  I 1 487 3 21.3 1 0 1  N 2.427 3.922 1.632 1  N N 0 0 0
91 1154 30 2  F 6  I 1 632 3 23.5 1 0 1  N 2.24 3.494 1.241 1  N N 0 0 0
92 68 37 3  M 1 III 1 137 3 19 5 3 1  N 4.162 1.09 1.08 1  N N 0 1 0
93 617 30 2  M 2  I 1 247 3 21 1 1 1  N 2.762 1.29 0.395 1  N N 0 1 1
94 1195 29 2  F 6 II 1 247 2 22.4 3 2 1  N 1.24 2.67 0.82 1  N N 0 0 0
95 913 34 2  M 1  I 1 238 1 20.5 1 1 1  N 5.228 3.225 1.015 1  N N 1 0 0
96 271 26 2  F 6 II 1 295 3 23.7 2 1 1  N 2.921 2.488 1.313 1  N N 0 0 0
97 817 36 3  F 6  I 1 289 2 25.4 1 3 1  N 3.51 2.46 0.9 1  N N 0 0 0
98 148 30 2  M 1 III 1 292 1 19.4 5 3 1  N 2.486 2.47 1.02 1  N N 0 0 0
99 10 38 3  F 6 II 1 242 2 21.4 4 2 1  N 3.25 3.71 0.976 1  N N 0 0 0
100 967 29 2  F 6 III 1 249 2 19.7 1 0 1  N 2.356 3.133 0.648 1  N N 0 0 1
101 266 28 2  F 6 II 1 123 3 19.5 1 1 1  N 6.075 3.389 0.891 1  N N 1 0 0
102 784 32 2  M 1 III 1 141 2 20.2 1 1 1  N 1.993 1.49 0.865 1  N N 0 1 0
103 627 41 3  M 2 III 1 172 3 21.2 1 1 1  N 5.19 2.1771 0.917 1  N N 1 1 0
104 157 32 2  F 6 III 1 337 2 22.4 5 3 1  N 1.57 3.106 0.934 1  N N 0 0 0
105 457 38 3  M 2 III 1 291 2 22.3 5 1 1  N 0.669 3.572 1.7 1  N N 0 0 0
106 66 30 2  F 6  I 1 674 3 19.8 1 2 1  N 1.893 3.5 0.82 1  N N 0 0 0
107 978 24 1  F 6  I 1 309 2 19.4 1 2 1  N 1.702 3.42 1.09 1  N N 0 0 0
108 824 30 2  F 2  I 1 294 3 21.8 1 1 1  N 0.909 2.5 1.45 1  N N 0 0 0
109 808 28 2  F 1 II 1 229 1 18.6 1 1 1  N 2.076 2.7 1.34 1  N N 0 0 0
110 1014 29 2  F 1 III 1 115 2 21.2 1 1 1  N 1.556 3.28 0.716 1  N N 0 0 1
111 781 28 2  M 1 III 1 128 3 18.5 1 1 1  N 7.534 3.45 1.015 1  N N 1 0 0
MASTER CHART ABBREVIATION
Occupation : Unskilled labourer : 1
Skilled labourer : 2
Lorry driver : 3
Commercial sex
worker
: 4
Office worker : 5
House wife : 6
Business man : 7
Route of transmission : Heterosexual : 1
Homosexual : 2
Opportunistic
infections
: Nil : 1
Oral candidiasis : 2
Candidiasis other
sites
: 3
Herpes zoster : 4
Tuberculosis : 5
Duration of HIV
infection
: < 1 years : 1
1-3 years : 2
> 3 years : 3
ART drugs : AZT : Zidovudine
3TC : Lamivudine
NVP : Nevirapine
EFZ : Efavirenz
Figure.1. Age distribution
Figure. 1a. Abnormal thyroid functional test in HIV positive individuals
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Figure. 3. TSH in pre ART and ART
Figure.4. FT 3 and FT 4
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Figure.4. FT 3 and FT 4
Fig. 5. Occupation
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Fig. 6. Route of transmission
Fig.7. WHO stage and TSH abnormality on HAART
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Fig.7a. WHO stage and FT 3 abnormality in patients on HAART
Fig. 8. Thyroid function test in patients on HAART
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